Crown Bioscience Inc. is a US-based biomedical outsourcing company, providing efficient and cost-effective solutions for global biotech and pharmaceutical companies. The company is headquartered in the heart of Silicon Valley, with a wholly owned research centers in Beijing China, and Indianapolis, US. They currently have 40,000 sq ft of modern biomedical research facility, including a 10,000 sq ft animal vivarium able to house immunodeficient small animals and large animal species.
The company is backed by two highly reputable venture capital firms based in the Silicon Valley: Acorn Campus Venture Fund, Desert Spring Life Science Capital, and Harbinger Venture.
Alex Wu, Ph.D.-- Chief Executive Officer
Dr. Alex Wu has over 20 years of experience in the biopharmaceutical industry and research. Before co-founding Crown Bioscience, he was CBO of Starvax, Inc., a biopharmaceutical R&D company. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. He also co-founded and was COO of Unimicro Technologies, a life science instrumentation company. Dr. Wu started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China and Ph.D. and MBA from University of California at Berkeley.
Faming Zhang, Ph.D.—President and CTO
Dr. Zhang had 12 years Pharmaceutical industry experience from Eli Lilly and Company. He had served as Global Head of Drug Discovery and Development Statistics and Information Sciences with responsibility in managing 7 information science groups in the field of Systems Biology, Genomics, Assay development, Chemoinformatics, and Tox/ADME statistics. Prior to the management role, he was a senior research scientist at Lilly leading the protein kinase/phosphatase crystal structure platform. He is one of the major contributors of the clinical candidate for cell cycle kinase inhibitors. Dr. Zhang was also pointed as project coordinator of anti-infectious disease target selection team responsible for 14 S. pneumoniae drug target selection from gene database to expression and crystallization. Dr. Zhang was the co-inventor of sever patents in the area of kinase inhibitors and novel anti-obesity protein therapeutics.
Dr. Zhang received his Ph.D in Biochemistry and Molecular Biology from Institute of Biophysics, Chinese Academy of Sciences and MBA degree from Kelly business school, Indiana University. He had a 4 year postdoctoral training in Protein Crystallography from University of Texas Southwestern Medical Center in Dallas and Photon Factory in Japan prior to joining Eli Lilly and Company. He is also an associate professor of Chemistry and Biochemistry program at Indiana University. Dr. Zhang has authored more than 30 scientific publications including 2 Nature articles.
Prior to joining Crown, Dr. Zhang has spent 12 years at Eli Lilly & Co. While at Lilly, he served as Global Head of Drug Discovery and Development, Statistics and Information Sciences. Prior to that, Dr. Zhang led Lilly's protein kinase/phosphatase crystal structure platform. He is the co-inventor of several patents in the area of kinase inhibitors and novel anti-obesity protein therapeutics. He also played a major role in the progression of cell cycle kinase inhibitors to the clinic. Dr. Zhang received his Ph.D in Biochemistry and Molecular Biology from Inst. of Biophysics, Chinese Academy of Sciences and an MBA from Kelly Business School, Indiana University. He had 4 year of postdoctoral training in Protein Crystallography from U. of Texas Southwestern Medical Center in Dallas. He is also an Assoc. Professor of Chemistry and Biochemistry at Indiana University. Dr. Zhang has authored more than 30 scientific publications.
Yiyou Chen, Ph.D.-- Chief Scientific Officer
Dr. Chen has over a decade of experience in drug R&D. Prior to co-founding Crown Bioscience Inc., he was Chief Scientific Officer and Co-founder of Starvax Inc., a biopharmaceutical company developing novel therapeutics against cancer and infectious disease. Before founding Starvax, Dr. Chen was a senior scientist and project leader at Palo Alto-based biotech company, Genencor International Inc., involved in research projects in animal modeling, protein engineering, and Immunology. Dr. Chen obtained his PhD in Experimental Pathology from University of Utah, and BS in Biochemistry from Peking University.
William Pan, Ph.D.--President, Crown Bioscience Inc. (Beijing)
Dr. William Pan obtained his B.S. in Biology from Sun Yat-sen University, Ph.D. in Molecular Biology from Sussex University, and had his postdoctoral training in University of California at Berkeley. He has more than 18 years of experiences in biopharmaceutical research and development and is a co-founder of Crown Bioscience Inc.. Dr. Pan was a research scientist and project leader at TerraGen Discovery Inc. (later acquired by Cubist Pharmaceuticals Inc.), and thereafter he co-founded and served as General Manager of TsingYuan TongMao Biotechnology Inc. in ShenZhen, China. Dr. Pan has also served as vice president of TsingHua YuanXing Biopharmaceutical Science and Technology Co., Inc., another ShenZhen-based biopharmaceutical company.
Jean-Pierre Wery, PhD. – Scientific Advisory Board Member
Dr. Wery is currently Chief Scientific Officer at Monarch Life Sciences, a company dedicated to the discovery and development of protein biomarkers. Prior to joining Monarch, Dr. Wery spent three years at Vitae Pharmaceuticals, Inc. where he was VP of Computational Drug Discovery. Before joining Vitae he worked for 12 years at Eli Lilly and Company in various scientific and management positions. Dr. Wery received his B.S. and Ph.D. in Physics from the U. of Liege, Belgium. Following his Ph.D., he did postdoctoral studies at Purdue University with Prof. Jack Johnson. Dr. Wery has authored more than 50 abstracts and publications.
As part of the complete preclinical service package, they have the capability to evaluate in vivo toxicology profile of test articles. Early toxicity evaluation can provide early assessment of drug safety profile, as well as provide guidance for efficacy study design. Their services include:
Single dose range finding and acute toxicity studies
Repeat dose tolerance study
Pharmackinetic and pharmacodynamic properties are critical for drug development. With our in-house bioanalytical capability, we are able to support both small molecule and large molecule drug development.
Analytical assay development
In-life phase sample collection (both small and large animal species)
Sample analysis via LC-MS/MS or ELISA
List of cancer cell lines
They carry the following tumor cells lines for our pre-clinical cancer pharmacology service. More cells can be obtained according customer request.
Human cancer cell lines:
• Breast cancer: MDA-MB-231, MCF-7, MDA-MB-435S, BT-474, T-47D
• Colorectal cancer: HT-29, HCT-116, SW480, SW620, DLD-1, LoVo, CACO-2
• Lung cancer: A549, NCI-H460, SK-MES-1, NCI-H69, SPC-A1
• Glioblastoma: U87MG, U118MG
• Prostate cancer: PC-3, DU-145, LNCaP,
• Liver cancer: HepG2, Hep3B, SK-HEP-1
• Ovarian cancer: NIH-OVCAR-3, SK-OV-3
• Fibrosarcoma: HT-1080
• Gastric cancer: NCI-N87, BGC823, MGC803
• Vulvar/epitheloid cancer: A431
• Melanoma: SK-MEL-5, A375
• Pancreatic cancer: Bx-PC-3, Panc-01, MIAPACA-2
• Kidney cancer: Caki-1, A498, 786-O, Caki-2
• Bladder cancer: ScaBER, 5637
• Head&Neck cancer: CNE-2
• Lymphoma: Daudi, Raji
• Leukemia: K562
• Myeloma: 8226
Murine cancer cell lines:
• Lung cancer: LLC
• Melanoma: B16F10
• Kidney cancer: RENCA